Repligen | RGEN - Operating Expenses


Repligen reported $174.27M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agilent USD 1.44B 27M Dec/2025
Align Technology USD 862.03M 39.18M Mar/2026
Bio Techne USD 235.92M 5.5M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Bruker USD 813.2M 87.7M Mar/2026
Charles River Laboratories USD 875.93M 42.48M Mar/2026
Danaher USD 52.95B 47.61B Mar/2026
Dentsply International USD 1.32B 895M Mar/2026
General Electric Aerospace USD 18.06B 7.11B Mar/2026
Henry Schein USD 3.17B 77M Mar/2026
Illumina USD 852M 51M Mar/2026
IQVIA Holdings USD 6.22B 4.53B Mar/2026
Mettler Toledo International USD 713.2M 64.61M Mar/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
OraSure Technologies USD 40.35M 2.45M Dec/2025
Pacific Biosciences Of California USD 97.83M 41.29M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Repligen USD 174.27M 3.67M Mar/2026
Revvity USD 628.34M 2.12M Mar/2026
Standard Biotools USD 45.72M 2.7M Dec/2025
Thermo Fisher Scientific USD 9.09B 821M Mar/2026
Waters USD 1.12B 457.15M Mar/2026
West Pharmaceutical Services USD 2.99B 2.35B Mar/2026